Status:

COMPLETED

Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat Epilepsy

Lead Sponsor:

cerbomed GmbH

Conditions:

Epilepsy

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

The aim of the study is to prove the feasibility and safety of transcutaneous, electrical stimulation of the vagus nerve in patients with difficult-to-treat forms of epilepsy.

Eligibility Criteria

Inclusion

  • Written Informed Consent
  • Patients of both gender, aged from 18-75 years
  • Diagnosis of epilepsy according to the diagnosis criteria of the DSM IV/ ICD 10 (especially G 40.1 /G 40.2/ G 40.3)
  • Insufficient response to at least one attempt of treatment in medical history with anticonvulsive medication, dosed sufficiently long and high
  • Antiepileptic Drugs (AED) therapy must be stable at a level that promises long-term continuity for at least 10 before study start and has to be continued for at least 3 months during treatment phase

Exclusion

  • Absence of Informed Consent
  • Pregnancy
  • Psychiatric diseases, especially post-traumatic stress disorder, obsessive-compulsive disorders, schizophrenia, Borderline personality disorders (BPD), character disorders as well as major depressive disorders, anxiety disorders and eating disorders as comorbidity.
  • Abuse of drugs and alcohol until 12 weeks before study start
  • Cerebrovascular diseases
  • Dementia
  • Severe traumatic brain injury in medical history including invasive and non-invasive methods of therapy (tumor surgery, "Gamma Knife Surgery")
  • Indications of structural impairment of the basal ganglia or the brain stem
  • active implants (e.g. cochlea implants, VNS, pacemaker)
  • Severe neurological diseases (e.g. Morbus Parkinson, systemic neurologic diseases
  • severe internistic diseases (e.g. arterial hypertension, respiratory failure)
  • Bronchial asthma
  • malignant diseases of any kind, within five years before study start
  • Severe active infectious diseases (e.g. HIV, hepatitis)
  • Bone diseases (e.g. Morbus Paget, recent fractures)
  • Diseases of the ENT body system: Hearing loss of the left ear which is treated with a hearing instrument, all dermatologic and infectious diseases which affect the area around the pinna and the ear canal, severe malformation of the pinna
  • Vagotomy
  • Concurrent participation in other studies
  • Other circumstances that in the opinion of the investigator might be an obstacle for enrolling the subject

Key Trial Info

Start Date :

August 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2011

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT01178437

Start Date

August 1 2009

End Date

January 1 2011

Last Update

March 8 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Epilepsiezentrum Erlangen

Erlangen, Bavaria, Germany, 91054